Table 6 Pairwise comparison (events per 100,000 persons per week) of the Pfizer/BioNtech and the Sinopharm vaccines (a) and Unvaccinated versus Sinopharm vaccinated individuals (b) in age cohorts > 50 and < 50 showing the rates of infections, hospitalisations, ICU admissions and deaths, p values and odds ratios.
From: Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain
Pfizer-BioNTech vs Sinopharm (after Jan 30) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALL | Over 50 | Under 50 | ||||||||||
Rate (Pfizer) | Rate (Sino) | p | OR | Rate (Pfizer) | Rate (Sino) | p | OR | Rate (Pfizer) | Rate (Sino) | p | OR | |
Infections | 136.28 | 350.53 | < .001 | 0.44 | 128.44 | 366.57 | < .001 | 0.39 | 139.65 | 345.52 | < .001 | 0.46 |
Hospitalisations | 2.82 | 28.36 | < .001 | 0.13 | 6.59 | 62.11 | < .001 | 0.12 | 1.74 | 14.74 | < .001 | 0.17 |
ICU admissions | 0.08 | 2.29 | < .001 | 0.04 | 0.36 | 6.62 | < .001 | 0.06 | 0.0 | 0.49 | 0.034 | 0.00 |
Deaths | 0.22 | 1.64 | < .001 | 0.15 | 0.96 | 5.45 | < .001 | 0.18 | 0.0 | 0.16 | NS 0.16 | 0.00 |
Unvaccinated vs Sinopharm (after Jan 30th) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALL | Over 50 | Under 50 | ||||||||||
Rate (Unvax) | Rate (Sino) | p | OR | Rate (Unvax) | Rate (Sino) | p | OR | Rate (Unvax) | Rate (Sino) | p | OR | |
Infections | 642.96 | 350.53 | < .001 | 1.72 | 781.32 | 366.57 | < .001 | 2.02 | 631.66 | 345.52 | < .001 | 1.70 |
Hospitalisations | 51.06 | 28.36 | < .001 | 1.78 | 225.55 | 62.11 | < .001 | 3.49 | 33.98 | 14.74 | < .001 | 2.35 |
ICU admissions | 6.39 | 2.29 | < .001 | 2.70 | 41.44 | 6.62 | < .001 | 5.92 | 2.65 | 0.49 | < .001 | 5.09 |
Deaths | 4.42 | 1.64 | < .001 | 2.72 | 37.17 | 5.45 | < .001 | 6.56 | 1.35 | 0.16 | NS 0.07 | 7.65 |
